Add to ORKGThe approval of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC) has expanded the armamentarium against this disease. This paper will review the historical progress and recent clinical developments of anti-EGFR therapies in the treatment of metastatic CRC. Novel strategies of targeting the EGFR pathway to improve efficacy as well as ongoing research in identifying specific molecular predictors of response will be discussed. Copyright © 2009 Herbert H. Loong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly ...
Item does not contain fulltextBACKGROUND: Two groups of agents targeting either the vascular endothe...
"Introduction: A number of anti-EGFR monoclonal antibodies (mAbs) have been recently developed for t...
BACKGROUND: Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indic...
The approval of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in the treatment ...
Copyright © 2012 Efat Azizi et al. This is an open access article distributed under the Creative Com...
Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial imp...
Despite being one of the most frequently diagnosed cancers worldwide, prognosis of metastatic colore...
Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorecta...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
The monoclonal antibodies against the epidermal growth factor receptor (EGFR) are active in patients...
Current US FDA-approved monoclonal antibodies targeting the EGF receptor (EGFR) include cetuximab an...
The epidermal growth factor receptor (EGFR) is a 170,000 Da transmembrane glycoprotein involved in s...
Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor recept...
Tianzhu Qiu,1,* Wensen Chen,2,* Ping Li,1 Jing Sun,1 Yanhong Gu,1 Xiaofeng Chen1 1Department of Onc...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Item does not contain fulltextBACKGROUND: Two groups of agents targeting either the vascular endothe...
"Introduction: A number of anti-EGFR monoclonal antibodies (mAbs) have been recently developed for t...
BACKGROUND: Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indic...
The approval of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in the treatment ...
Copyright © 2012 Efat Azizi et al. This is an open access article distributed under the Creative Com...
Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial imp...
Despite being one of the most frequently diagnosed cancers worldwide, prognosis of metastatic colore...
Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorecta...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
The monoclonal antibodies against the epidermal growth factor receptor (EGFR) are active in patients...
Current US FDA-approved monoclonal antibodies targeting the EGF receptor (EGFR) include cetuximab an...
The epidermal growth factor receptor (EGFR) is a 170,000 Da transmembrane glycoprotein involved in s...
Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor recept...
Tianzhu Qiu,1,* Wensen Chen,2,* Ping Li,1 Jing Sun,1 Yanhong Gu,1 Xiaofeng Chen1 1Department of Onc...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Item does not contain fulltextBACKGROUND: Two groups of agents targeting either the vascular endothe...
"Introduction: A number of anti-EGFR monoclonal antibodies (mAbs) have been recently developed for t...
BACKGROUND: Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indic...